REGN Stock Gains 3.60%, RSI Overbought In Focus

Regeneron Pharmaceuticals closed at $961.26 on Monday, November 2, after a 19.02% advance over five sessions, with trading volume reaching 2.1 times its 20-day average. The move brought the drugmaker’s shares to their 20-day resistance and close to the three-month high, while a new golden cross and rising On-Balance Volume (OBV) point to broad technical strength. But momentum gauges are already in overbought territory, making the rally’s durability the central question.

Trend & Price Action

The latest close sits above both the 20-day simple moving average (SMA) of $800.63 and the 50-day SMA of $795.85. The 20-day average rose 4.11% over five days, and crossed above the 50-day average in the latest session. This “golden cross” is often read as a shift toward stronger near-term momentum, though it confirms a trend rather than guaranteeing that it will continue. The price structure has strengthened quickly: Regeneron gained 32.32% over one month and ended at the upper boundary of its 20-day range. It is also near the three-month high of $974.00. That proximity matters in both directions: a move above the high would extend the advance, while a failure to clear it could leave the shares vulnerable to profit-taking after a sharp run. As shown in the chart, the close is above the upper Bollinger Band at $911.77. Bollinger Bands track how far prices have moved from a recent average; a close beyond the band can signal powerful momentum, but also a move stretched relative to recent trading. The bands have widened to 27.8%, indicating elevated volatility rather than a quiet, orderly climb.

Oscillators & Momentum

The momentum indicators reinforce the strength of the move, but also warn that it may be extended. The 14-day Relative Strength Index (RSI) is 81.9, in overbought territory; the Stochastic reading is 94.2% for %K and 93.1% for %D, also overbought. These readings do not, by themselves, signal an imminent reversal. They show that buying pressure has been unusually strong and that the shares may be more sensitive to a pause or pullback. The Moving Average Convergence Divergence (MACD), a trend-and-momentum measure, remains positive: its reading is 30.041, above the 12.915 signal line, with a positive 17.126 histogram. That alignment supports the uptrend rather than contradicting it. As shown in the chart, the tension is between positive MACD momentum and the stretched RSI and Stochastic readings.

Volatility, Volume & Key Levels

Volume reached 1,660,200 shares, versus a 20-day average of 793,225. The 2.1-times surge, alongside rising OBV, suggests the advance has attracted participation rather than occurring on thin trading. OBV adds volume on rising sessions and subtracts it on falling ones; its upward direction is consistent with accumulation, although it cannot establish how long that demand will last. The 14-day Average True Range (ATR), a measure of typical price movement, stands at $29.43, or 3.1% of the share price. That points to meaningful day-to-day swings. The reference level at $917.12, calculated as the latest price minus 1.5 times ATR, offers a nearer risk marker than the 20-day support at $738.72, which lies much farther below. The nearest overhead test is the $974.00 three-month high, just above the latest close of $961.26 and the 20-day resistance at that same closing level. A sustained break above $974.00 would put the next reference level at $1,005.40, the price plus 1.5 times ATR. If the shares fail to hold $917.12, the recent momentum would be under pressure; a deeper retreat would bring the $738.72 20-day support into focus.

Technical Verdict: BUY

The technical bias is bullish, supported by three signals and no bearish signals in the supplied assessment. The strongest evidence is the latest-session golden cross, a close above the 20-day high on volume at least 1.5 times its average, and rising OBV. The main counterweight is the overbought RSI of 81.9, alongside an overbought Stochastic; these raise pullback risk without overturning the trend signals. The verdict is invalidated if the price falls below $917.12, the price-minus-1.5-times-ATR reference level.

• Ideal entry range: $917.12–$961.26, using the ATR-based reference and 20-day resistance.
• Exit target: $974.00, the three-month high and next resistance above the current 20-day ceiling.
• Stop-loss protection: $917.12, the price-minus-1.5-times-ATR level.

In plain English, the trend signals remain positive, but the shares’ stretched momentum makes a pullback a clear risk.

Metric	Reading
Last price	$961.26
One-day / five-day / one-month change	3.60% / 19.02% / 32.32%
SMA20 / SMA50	$800.63 / $795.85
RSI(14) / Stochastic %K, %D	81.9 / 94.2, 93.1
MACD / signal / histogram	30.041 / 12.915 / 17.126
Volume / 20-day average	1,660,200 / 793,225
20-day support / resistance	$738.72 / $961.26
Three-month low / high	$722.02 / $974.00

Summary Data REGN

Last price	961.26 USD
Change 1 day / 5 days / 1 month	3.60% / 19.02% / 32.32%
Trend / MA-cross	uptrend / golden
SMA20 / SMA50	800.63 / 795.85
RSI (14) / Stochastic %K	81.9 / 94.2
Bollinger %B / ATR	122% / 29.43
Support / Resistance 20 days	738.72 / 961.26
Data as of	3 November 2026 04:00 WIB

Disclaimer: This technical analysis is generated automatically from exchange data and indicators calculated by JournalArta, for information and education only. The verdict and the entry, target and stop-loss levels are not investment advice or a solicitation to buy or sell any security. Investment decisions and their risks rest solely with the reader.